GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » Shiller PE Ratio

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Shiller PE Ratio

: (As of Today)
View and export this data going back to 1990. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Teva Pharmaceutical Industries Shiller PE Ratio Historical Data

The historical data trend for Teva Pharmaceutical Industries's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => - [6] => - [7] => - [8] => - [9] => - )
Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries Shiller PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's Shiller PE Ratio falls into.



Teva Pharmaceutical Industries Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Teva Pharmaceutical Industries's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Teva Pharmaceutical Industries's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.41/129.4194*129.4194
=0.410

Current CPI (Dec. 2023) = 129.4194.

Teva Pharmaceutical Industries Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.870 99.695 1.129
201406 0.870 100.560 1.120
201409 1.020 100.428 1.314
201412 0.800 99.070 1.045
201503 0.520 99.621 0.676
201506 0.630 100.684 0.810
201509 0.120 100.392 0.155
201512 0.550 99.792 0.713
201603 0.620 100.470 0.799
201606 0.200 101.688 0.255
201609 0.350 101.861 0.445
201612 -1.110 101.863 -1.410
201703 0.570 102.862 0.717
201706 -5.940 103.349 -7.438
201709 0.520 104.136 0.646
201712 -11.410 104.011 -14.197
201803 1.030 105.290 1.266
201806 -0.240 106.317 -0.292
201809 -0.270 106.507 -0.328
201812 -2.850 105.998 -3.480
201903 -0.100 107.251 -0.121
201906 -0.630 108.070 -0.754
201909 -0.290 108.329 -0.346
201912 0.100 108.420 0.119
202003 0.060 108.902 0.071
202006 0.130 108.767 0.155
202009 -3.970 109.815 -4.679
202012 0.140 109.897 0.165
202103 0.070 111.754 0.081
202106 0.190 114.631 0.215
202109 0.260 115.734 0.291
202112 -0.140 117.630 -0.154
202203 -0.860 121.301 -0.918
202206 -0.210 125.017 -0.217
202209 0.050 125.227 0.052
202212 -1.100 125.222 -1.137
202303 -0.180 127.348 -0.183
202306 -0.770 128.729 -0.774
202309 0.070 129.860 0.070
202312 0.410 129.419 0.410

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Teva Pharmaceutical Industries  (NYSE:TEVA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Teva Pharmaceutical Industries Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Executives
Dov Bergwerk officer: Acting Chief Legal Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif officer: EVP, Chief Financial Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss officer: Chief Accounting Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant officer: EVP, Business Development C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs officer: EVP Global Marketing&Portfolio 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape officer: Executive VP Global Operations C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark officer: Exec. VP Chief Legal Officer 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell officer: Exec. VP, European Commercial 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis officer: President and CEO IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir officer: Executive VP, Global R&D 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani officer: EVP,Global Marketing&Portfolio C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX